Asunaprevir (CAS 630420-16-5)
See product citations (4)
QUICK LINKS
Asunaprevir is a potent inhibitor of the NS3/4A protease, an enzyme critical for the replication of the hepatitis C virus (HCV). By binding to this protease, asunaprevir blocks the cleavage of the HCV polyprotein, a process essential for the production of mature viral proteins that are necessary for the virus′s life cycle. This specific inhibition disrupts the viral replication cycle, significantly reducing the ability of the virus to proliferate. Its role in research has been instrumental in understanding the complexities of HCV replication and in the development of targeted antiviral strategies. Studies involving asunaprevir have shed light on the molecular mechanisms of HCV resistance, the dynamics of viral suppression, and the potential for combination therapies with other antiviral agents. This knowledge has not only advanced the scientific community′s understanding of HCV but also paved the way for the exploration of similar therapeutic strategies against other viral infections.
Asunaprevir (CAS 630420-16-5) References
- Daclatasvir + asunaprevir: first global approval. | Poole, RM. 2014. Drugs. 74: 1559-71. PMID: 25117197
- Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. | Akuta, N., et al. 2016. J Med Virol. 88: 506-11. PMID: 26292191
- Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir. | Barrail-Tran, A., et al. 2015. Antimicrob Agents Chemother. 59: 7903-5. PMID: 26438504
- Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. | Swallow, E., et al. 2016. J Comp Eff Res. 5: 273-9. PMID: 26793987
- Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir. | Chayama, K. and Hayes, CN. 2017. J Gastroenterol. 52: 125-126. PMID: 27541041
- Asunaprevir: An HCV Protease Inhibitor With Preferential Liver Distribution. | Eley, T., et al. 2017. Clin Pharmacol Drug Dev. 6: 195-200. PMID: 28263460
- Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1. | Kao, JH., et al. 2017. J Gastroenterol Hepatol. 32: 1998-2005. PMID: 28370350
- Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus. | Tsai, WL., et al. 2017. Front Microbiol. 8: 668. PMID: 28473813
- The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients. | Taki, S., et al. 2018. Gut Liver. 12: 86-93. PMID: 28798288
- Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience. | Ikegami, T., et al. 2017. Clin Transplant. 31: PMID: 28881052
- Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b. | Liu, Y., et al. 2018. Clin Drug Investig. 38: 427-437. PMID: 29417464
- Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects. | Osawa, M., et al. 2019. J Clin Pharmacol. 59: 557-565. PMID: 30566237
- Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. | Osawa, M., et al. 2019. Clin Pharmacol Drug Dev. 8: 802-817. PMID: 30629858
- Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation. | Lim, YS., et al. 2021. Mol Cells. 44: 688-695. PMID: 34518443
- Real-world long-term analysis of daclatasvir plus asunaprevir in patients with hepatitis C virus infection. | Fujii, H., et al. 2022. JGH Open. 6: 344-352. PMID: 35601120
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Asunaprevir, 5 mg | sc-364414 | 5 mg | $590.00 | |||
Asunaprevir, 25 mg | sc-364414A | 25 mg | $1479.00 |